Trial Search Results

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

The purpose of this trial is to study standard pelvic lymphadenectomy to see how well it works compared to extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Southwest Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Procedure: therapeutic conventional surgery
  • Procedure: therapeutic standard lymphadenectomy
  • Procedure: therapeutic extended lymphadenectomy





   - Histologically confirmed urothelial carcinoma of the bladder

      - Stage T2, T3, or T4a disease

         - No clinical stage consistent with a low-risk of node metastasis (CIS only,

         - No T4b disease (fixed lesion)

      - Disease that requires primary radical cystectomy and lymph node dissection for
      definitive treatment

         - No laparoscopic surgery

   - Predominant urothelial carcinoma with any of the following elements allowed:

      - Adenocarcinoma

      - Squamous cell carcinoma

      - Micropapillary or minor components of other rare phenotype

      - No pure squamous cell carcinoma or adenocarcinoma

   - No visceral or nodal metastatic disease proximal to the common iliac bifurcation by
   2-view chest x-ray and abdominal-pelvic imaging by computerized tomography or MRI of
   the abdomen and pelvis

   - No intra-operative pelvic lymph node involvement (confirmed by frozen section) at or
   above the bifurcation of the common iliac vessels in any of the extended template


   - Zubrod performance status 0-2

   - ALT and AST ≤ upper limit of normal (ULN)*

   - Alkaline phosphatase ≤ ULN*

   - Not pregnant or nursing

   - Fertile patients must use an effective contraception

   - No other prior malignancy except adequately treated basal cell or squamous cell skin
   cancer, in situ cervical cancer, or stage I or II cancer from which the patient is in
   complete remission for the past 5 years

   - Medically suitable to undergo cystectomy, in the physician's opinion NOTE: *Levels may
   be ≥ ULN provided metastatic disease is excluded using dedicated liver imaging, bone
   scan, or biopsy.


   - See Disease Characteristics

   - No prior partial cystectomy for invasive bladder cancer

   - No prior pelvic surgery that would obviate a complete extended lymphadenectomy (e.g.,
   aorto-femoral/iliac bypass)

   - Prior neoadjuvant chemotherapy for this cancer allowed provided it has been completed
   and patient has recovered

   - No prior pelvic irradiation

Ages Eligible for Study

18 Years - 120 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting